Selected 10 publications by Serhiy Souchelnytskyi.
1. New modality of diagnostic for personalization of cancer treatment, Functional Molecular Diagnostic (FMDx). FMDx has been used to help in treatment of cancer patients in Sweden and abroad (Germany, the UK, Poland and Ukraine). DOI: 10.13140/2.1.1704.0645
2. New modality of personalization of anti-cancer treatment, presented in 2 papers for two types of cancer. Attarha S., Mints M., Andersson S., Souchelnytskyi S. (2013) Individualized proteome profiling of human endometrial tumours improves detection of new prognostic markers. Br. J. Cancer, doi: 10.1038/bjc2013.359. Zakharchenko O., Cojoc M., Dubrovska A., Souchelnytskyi S. (2013) A role of TGFß1 dependent 14-3-3σ phosphorylation at Ser69 and Ser74 in the regulation of gene transcription, stemness and radioresistance. PLoS ONE, 8(5):e65163. doi: 10.1371/journal.pone.0065163.
3. New mechanisms of TGFbeta signalling. Lin K.W., Yakymovych I., Jia M., Yakymovych M., Souchelnytskyi S. (2010) Phosphorylation of eukaryotic elongation factor eEF1A1 at Ser300 by type I transforming growth factor-beta receptor results in inhibition of mRNA translation. Current Biology, 20(18), 1615-1625. Top 10 downloads by the Cell Press.
4. Development of novel diagnostic proteome signature; it is now used in the clinic: Jia M., Souchelnytskyi N., Hellman U., O’Hare M. Jat P.S., Souchelnytskyi S. (2010) Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is down-regulated in human breast cancer. Proteomics Clinical Applications, 4, 816-828.
5. Successful application of systems biology to exploration of the systemic signalling by TGFbeta: Bhaskaran N., Souchelnytskyi S. (2008) Systemic analysis of TGFbeta proteomics revealed involvement of Plag1/CNK1/ RASSF1A/Src network in TGFbeta1-dependent activation of Erk1/2 and cell proliferation. Proteomics, 8 (21), 4507-4520.
6. First phosphoproteomics study of TGFbeta signalling: Stasyk T., Dubrovska A., Lomnytska M., Wernstedt C., Heldin C.-H., Hellman U., Souchelnytskyi S. (2005) Phosphoproteome profiling of transforming growth factor-beta signalling: abrogation of TGFbeta1-dependent phosphorylation of TFII-I enhances cooperation of TFII-I and Smad3 in transcription. Mol. Biol. Cell, doi10.1091/mbc, 16, 4765-4780.
7. Discovery of markers for early detection of breast and ovarian cancer. These markers are now in clinical development: Lomnytska M., Dubrovska A., Hellman U., Volodko N., Souchelnytskyi S. (2005) Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int. J. Cancer, doi10.1002/ijc.21332, in paper: (2006) 118, 412-421.
8. First report of the cross-talk between BRCA1 and TGFbeta signalling: Dubrovska A., Kanamoto T., Lomnytska M., Heldin C.-H., Volodko N., Souchelnytskyi S. (2005) TGFbeta/Smad3 counteracts BRCA1-dependent repair of DNA damage. Oncogene, 21, 2289-2297.
9. First expression proteomics study of TGFbeta signalling, which showed a new signalling mode of TGFbeta to regulation of DNA repair: Kanamoto T., Hellman U., Heldin C.-H., Souchelnytskyi S. (2002) Functional proteomics of transforming growth factor-1 stimulated Mv1Lu cells; Rad51 as a target of TGFbeta1-dependent regulation of DNA repair. EMBO J., 21(5), 1219-1230.
10. Discover of a new signalling mechanisms of TGFbeta, with implication to tumorigenesis: Yakymovych I., ten Dijke P., Heldin C.-H., Souchelnytskyi S. (2001) Regulation of Smad signaling by protein kinase C. The FASEB Journal, 10.1096/fj.00-0474fje, 15 (3), 553-555.
Skriv ditt stycke här.
PhD, Professor, Cancer Proteomics and Systems Biology for Personalized Medicine
What has been achieved?
This can be in clinic already now:
1. Functional Molecular Diagnostic (FMDx)
2. Markers for early detection of breast and ovarian cancers
3. Markers to discriminate benign from malignant neoplasia
4. Proteome signatures for prediction of aggressiveness of human breast cancer
5. Implementation of meta-data analysis (systems biology) for individualization of treatment of cancer patients
To attention of drug developers
6. Assays for monitoring efficiency of TGFbeta signalling-addressing drugs in in vivo models
7. Proteomics-based technology for monitoring of specificity of kinase inhibitors
Important findings reported in publications
8. Extensive contribution to studies of TGFbeta signaling in cancer, from first in Europe purification of TGFbeta, studies of TGFbeta receptors and Smad proteins, to studies of systemic properties of TGFbeta signaling.
9. Reporting proteome signatures of immortalization, high proliferation rate and invasiveness of human breast epithelial cells.
10. New concept for intracellular signalling: first report of a direct interaction between a Ser/Thr kinase receptor (BMPRII) and a Tyr kinase receptor.
11. Definition of rules for the application of systems biology to proteomics.